Monitoring Treatment Response in Hormonal Transitions

MARKABLE Research Team · May 2026 · 7 min read

Between 50% and 65% of women who start hormone replacement therapy (HRT) discontinue within the first year. This is not because HRT does not work. In most cases, it does. The problem is a monitoring gap: patients and clinicians lack the structured, longitudinal data needed to evaluate whether treatment is working, to optimize dosing, and to maintain the treatment conversation over time.

The discontinuation problem

The data on HRT adherence is sobering. A 2021 analysis published in Menopause found that 53% of women prescribed HRT had discontinued within 12 months. A UK study by Cumming et al. found rates as high as 65% at one year. The reasons cited most frequently:

53%

of women prescribed HRT discontinue within 12 months

Source: Bhavnani BR & Strickler RC, Menopause, 2021

Uncertainty about whether it is working (reported by 30-40% of those who discontinue)
Side effects in the adjustment period that are not adequately managed
Fear of long-term risks, often based on outdated information from the 2002 WHI headlines
Lack of follow-up: many women receive a prescription and are not seen again for months
Insufficient dose optimization: initial dosing may be too low or too high, and without monitoring, adjustments are delayed

The core issue: In most areas of medicine, treatment response is monitored with objective data. Blood pressure medication is evaluated with blood pressure readings. Diabetes treatment is tracked with HbA1c. But menopause treatment is typically evaluated by asking "how do you feel?" at a follow-up appointment months later, relying entirely on patient recall.

The monitoring gap

The current standard of care for monitoring HRT response typically involves:

An initial prescription based on symptoms and clinical judgment
A follow-up appointment at 3-6 months
An annual review thereafter

Between these touchpoints, there is usually no structured data collection. The patient may or may not track her own symptoms. The clinician relies on the patient's recollection at the follow-up visit, which is subject to recall bias and recency effects.

This gap creates several problems:

Delayed dose optimization

HRT dosing is highly individual. The optimal dose of transdermal estradiol, for example, varies widely. Without frequent monitoring, a patient on a suboptimal dose may wait 3-6 months before an adjustment, experiencing unnecessary symptoms in the interim.

Side effect management

Many side effects of HRT (breast tenderness, breakthrough bleeding, mood changes) occur in the first 8-12 weeks and then resolve. But without proactive monitoring and communication, patients may discontinue before the adjustment period is complete.

Erosion of treatment confidence

When patients cannot see objective evidence that their treatment is working, doubt creeps in. The lingering cultural anxiety around HRT (a legacy of the initial WHI reporting) amplifies this doubt. Objective data showing improvement over time can counteract uncertainty with evidence.

What to track

Effective treatment monitoring for hormonal transitions should capture multiple domains:

Symptom burden

Vasomotor symptoms: Frequency and severity of hot flashes and night sweats (ideally tracked daily or weekly)
Sleep quality: Time to fall asleep, nighttime awakenings, subjective rest quality
Mood: Anxiety, irritability, depressive symptoms, using validated brief scales
Urogenital symptoms: Dryness, discomfort, urinary symptoms
Musculoskeletal: Joint pain and stiffness, which are estrogen-responsive symptoms often overlooked

Cognitive function

Processing speed: Objective tests of reaction time and cognitive throughput
Verbal memory: Word recall and verbal learning tasks
Executive function: Task switching, working memory capacity
Cognitive improvement is often one of the earliest measurable responses to HRT but is rarely tracked objectively

4-6 wks

Typical time to initial symptom improvement on HRT, though full optimization may take 3-6 months

Source: NAMS Position Statement on Hormone Therapy, 2022

Biomarkers (when appropriate)

Serum estradiol: Useful for confirming absorption of transdermal preparations or dosing adequacy, though not routinely recommended for all patients
FSH: May help confirm suppression on combined HRT regimens
Lipid panel and metabolic markers: To monitor cardiovascular and metabolic effects
Endometrial monitoring: Ultrasound assessment when indicated by bleeding patterns

How longitudinal data changes the conversation

When patients and clinicians have access to structured, longitudinal treatment data, several things change:

Visible progress builds adherence

A patient who can see that her hot flash frequency dropped from 8 per day to 2 per day over 6 weeks has concrete evidence that treatment is working. This is far more persuasive than trying to recall whether things feel "better" at a 3-month follow-up.

Pattern recognition enables optimization

Longitudinal data can reveal patterns that are invisible in episodic visits. For example, a patient whose symptoms improve for 3 weeks of her HRT cycle but recur in the fourth week may benefit from dose adjustment that would never be identified without continuous tracking.

Shared data improves clinical efficiency

When a patient arrives at a follow-up with structured symptom data covering the intervening months, the appointment can focus on clinical decision-making rather than history-taking. The NAMS 2022 Position Statement on hormone therapy emphasizes the importance of individualized, ongoing assessment, which structured data supports.

The analogy: Imagine managing diabetes without a glucometer, relying solely on how the patient felt at quarterly visits. That is essentially the current state of menopause treatment monitoring. Longitudinal, multi-domain tracking is the equivalent of giving both patient and clinician a continuous data stream.

Patient engagement and shared decision-making

Treatment monitoring is not just a clinical tool. It is a patient engagement strategy. Research on chronic disease management consistently shows that patients who actively track their health data are more adherent to treatment, more satisfied with care, and more likely to continue therapy long-term.

For menopause treatment specifically:

Self-monitoring reinforces the patient's sense of agency over her health
Objective data reduces the influence of fear-based media narratives about HRT
Shared data facilitates genuine shared decision-making, the patient and clinician are looking at the same evidence
Monitoring creates natural touchpoints for dose adjustment conversations before the patient decides to quit

The bottom line

The high discontinuation rate for HRT is not primarily a medication problem. It is a monitoring problem. When patients and clinicians lack structured, longitudinal data on treatment response, uncertainty fills the void, and uncertainty drives discontinuation.

Closing the monitoring gap, through systematic symptom tracking, objective cognitive assessment, and appropriate biomarker measurement, has the potential to improve treatment adherence, optimize outcomes, and transform the clinical conversation from "how do you feel?" to "here is what the data shows."

Close the monitoring gap in your practice

MARKABLE provides longitudinal, multi-domain wellness tracking that gives clinicians and patients the objective data needed to evaluate treatment response and optimize care over time.

See How MARKABLE Works for Clinics →

This article is for informational purposes only and does not constitute medical advice. MARKABLE is a general wellness product for personal awareness and self-monitoring. It is not a medical device and is not intended to diagnose, treat, cure, or prevent any disease. Treatment decisions should be made in consultation with a qualified healthcare provider based on individual clinical circumstances and current practice guidelines.